{
    "clinical_study": {
        "@rank": "38324", 
        "arm_group": {
            "arm_group_label": "Proton Radiation", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The current trial will provide important data on the recurrence rates and patterns of\n      failure using state of the art target agent, chemotherapy and proton beam technology for\n      patients with Locally Advanced Pancreatic Cancer (LAPC). A median survival of 10 months or\n      greater would be considered evidence of a regimen potentially worthy of further study as a\n      new treatment paradigm in one arm in a future phase III trial."
        }, 
        "brief_title": "Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed unresectable non-metastatic adenocarcinoma\n             of the pancreas\n\n          -  AJCC stage I-III with unresectable or borderline unresectable disease as defined by\n             NCCN guidelines\n\n          -  Radiological resectability is defined by the following criteria on abdominal imaging:\n\n               1. No evidence of tumor extension to the celiac axis, hepatic artery or superior\n                  mesenteric artery.\n\n               2. No evidence of tumor encasement or occlusion of the superior mesenteric vein\n                  (SMV) or the SMV/portal vein confluence\n\n               3. No evidence of visceral or peritoneal metastases\n\n          -  Borderline and Unresectable cases would be defined as those that do not meet the\n             criteria in section and also show no evidence of distant metastatic or\n             intraperitoneal disease.\n\n          -  Eastern Cooperative Oncology Group performance status of \u2264 2\n\n          -  Age > 18 years\n\n          -  Adequate hematologic reserve, hepatic reserve and renal function\n\n          -  WBC > 2,000 cells/mm3\n\n          -  ANC > 1,500 cells/mm3\n\n          -  Platelets > 100,000 cells/mm3\n\n          -  Serum bilirubin \u2264 2.5 mg/dL\n\n          -  Serum creatinine \u2264 2 x upper limit of normal (ULN), or creatinine clearance (Ccr) \u2265\n             30ml/min\n\n          -  ALT < 3 times ULN\n\n          -  AST < 3 times ULN\n\n          -  Albumin > 3.2 g/dl\n\n          -  Patient must sign study-specific informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01683422", 
            "org_study_id": "5110324"
        }, 
        "intervention": [
            {
                "arm_group_label": "Proton Radiation", 
                "description": "Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.\nPost-proton chemotherapy:  To be started in 4 to 6 weeks after completion of proton chemotherapy.  Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days.  The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles.", 
                "intervention_name": "Proton, Gemcitabine, Erlotinib, Capecitabine", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Proton Radiation", 
                "intervention_name": "Proton Radiation", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Capecitabine", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 11, 2014", 
        "location": {
            "contact": {
                "email": "gyang@llu.edu", 
                "last_name": "Gary Yang, MD", 
                "phone": "909-558-4280"
            }, 
            "contact_backup": {
                "last_name": "Proton Referral", 
                "phone": "1 800 496-4966"
            }, 
            "facility": {
                "address": {
                    "city": "Loma Linda", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92354"
                }, 
                "name": "Loma Linda University Medical Center"
            }, 
            "investigator": {
                "last_name": "Gary Yang, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial of Gemcitabine and Erlotinib (GE) Plus Proton-chemotherapy (PCT) and Capox for Locally Advanced Pancreatic Cancer (LAPC)", 
        "overall_contact": {
            "email": "gyang@llu.edu", 
            "last_name": "Gary Yang, MD", 
            "phone": "909-558-4280"
        }, 
        "overall_contact_backup": {
            "email": "scteichm@llu.edu", 
            "last_name": "First Call: Proton Referral RN Backup: Sandi Teichman", 
            "phone": "1 800 776-8667"
        }, 
        "overall_official": {
            "affiliation": "Loma Linda University", 
            "last_name": "Gary Yang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To determine the one-year survival rate", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01683422"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Loma Linda University", 
            "investigator_full_name": "Gary Yang, MD", 
            "investigator_title": "MD, Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "To evaluate the frequency of serious adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Ongoing"
        }, 
        "source": "Loma Linda University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Loma Linda University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}